ABIRATERONE TEVA 250 MG

البلد: إسرائيل

اللغة: الإنجليزية

المصدر: Ministry of Health

العنصر النشط:

ABIRATERONE ACETATE

متاح من:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

ATC رمز:

L02BX03

الشكل الصيدلاني:

TABLETS

تركيب:

ABIRATERONE ACETATE 250 MG

طريقة التعاطي:

PER OS

نوع الوصفة الطبية :

Required

المصنعة من قبل:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

المجال العلاجي:

ABIRATERONE

الخصائص العلاجية:

Abiraterone Acetate is CYP17 inhibitor indicated:- in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.- for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).

تاريخ الترخيص:

2017-06-27

نشرة المعلومات

PATIENT PACKAGE INSERT
IN ACCORDANCE WITH THE
PHARMACISTS’ REGULATIONS
)PREPARATIONS( – 1986
The medicine is dispensed with
a doctor’s prescription only
ABIRATERONE TEVA 250 MG
TABLETS
EACH TABLET CONTAINS:
Abiraterone acetate 250 mg
For information on the inactive and allergenic
ingredients, see section 2 “Important
information about some of the ingredients
of the medicine” and section 6 – “Further
Information”.
READ THE LEAFLET CAREFULLY IN ITS ENTIRETY
BEFORE USING THE MEDICINE. This leaflet
contains concise information about the
medicine. If you have further questions, refer
to the doctor or pharmacist.
The medicine is not intended for use in
women, children or adolescents.
This medicine has been prescribed to treat
your ailment. Do not pass it on to others. It
may harm them even if it seems to you that
their ailment is similar.
1. WHAT IS THE MEDICINE INTENDED
FOR?
Abiraterone Teva is a prescription medicine
containing an active ingredient called
abiraterone acetate.
Abiraterone Teva, a CYP17 enzyme inhibitor,
is given together with prednisone for the
treatment of metastatic castration-resistant
prostate cancer.
Likewise, it is intended for treatment of
adult men newly diagnosed with high-risk,
metastatic, hormone-sensitive, prostate
cancer )mHSPC(, in combination with
androgen deprivation therapy )ADT(.
THERAPEUTIC GROUP:
Specific CYP17 enzyme inhibitor.
2. BEFORE USING THE MEDICINE
DO NOT USE THE MEDICINE IF:
• You are sensitive )allergic( to abiraterone
acetate or to any of the additional
ingredients contained in the medicine.
For the list of the additional ingredients,
see section 6 “Further Information”.
• You are pregnant or might be pregnant.
Abiraterone Teva is not intended for use
in women.
• You are breastfeeding.
• Women who are pregnant or who might
be pregnant must not touch Abiraterone
Teva without protection. They must take
protective measures, such as wearing
gloves, if they must touch the medicine.
• You are suffering from severe liver
function problems.
SPECIAL